In addition, for patients affected by breast and/or ovarian cancer, knowledge about their BRCA1/2 mutation status is important because it determines the therapeutic response [1] and choice of medication (e.g., PARP inhibitors [2]). The gene discussed is BRCA1; the disease is ovarian carcinoma.